Literature DB >> 9706806

Improved prognosis of heart failure due to idiopathic dilated cardiomyopathy in children.

P Venugopalan1, A K Agarwal, F O Akinbami, I B El Nour, R Subramanyan.   

Abstract

We analyzed the outcome of 18 children with idiopathic dilated cardiomyopathy (IDC). There was a striking female preponderance (M:F = 1:3.5) and 15 (83%) presented below the age of 2 years. Follow up for a mean duration of 3.5 years revealed complete recovery in seven (43%) and an additional three (19%) became asymptomatic. Three (19%) died and another three (19%) continued to be symptomatic but in controlled heart failure. Two were lost to follow up. Among those who improved, the majority (75%) did so in 1.5 years. Three of five patients who received periodic dobutamine infusion showed improvement in quality of life. The survivals of 94% at 1 year and 87% at 3 years are significantly better than those previously reported. This is the first such study of IDC in children from the Arab peninsula.

Entities:  

Mesh:

Year:  1998        PMID: 9706806     DOI: 10.1016/s0167-5273(98)00084-9

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Outcome Predictors for Pediatric Dilated Cardiomyopathy: A Systematic Review.

Authors:  Jorge A Alvarez; James D Wilkinson; Steven E Lipshultz
Journal:  Prog Pediatr Cardiol       Date:  2007-09-01

2.  A long-term follow-up of a girl with dilated cardiomyopathy after mitral valve replacement and septal anterior ventricular exclusion.

Authors:  Shiro Baba; Hiraku Doi; Tadashi Ikeda; Masashi Komeda; Tatsutoshi Nakahata
Journal:  J Cardiothorac Surg       Date:  2009-09-23       Impact factor: 1.637

3.  Pediatric idiopathic dilated cardiomyopathy: A single center experience.

Authors:  Ahmad S Azhar
Journal:  J Nat Sci Biol Med       Date:  2013-01

4.  Pattern of congestive heart failure in a Kenyan paediatric population.

Authors:  Julius A Ogeng'o; Patrick M Gatonga; Beda O Olabu; Diana K Nyamweya; Dennis Ong'era
Journal:  Cardiovasc J Afr       Date:  2013-05       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.